Forum

Your browser does not seem to support JavaScript. As a result, your viewing experience will be diminished, and you have been placed in read-only mode.

Please download a browser that supports JavaScript, or enable it if it's disabled (i.e. NoScript).

The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

71 - As per 6.6d and the exemption of "now on provincial formulary", does this apply to a change in formulary status? As an example "Product Y has a new formulary status". This is of course would not be linked to a therapeutic message but is intended to inform the audience of a change in formulary status. Would such a mention be PAAB exempt?

FYI post-approval change/preclearance exemption/what requires review/PAAB scope

1 Posts 1 Posters 340 Views 1 Watching

J Offline
J Offline
Jennifer Carroll

wrote on last edited by

#1

The exemption would still apply given that it remains a "formulary announcement" not linked to any therapeutic message. However, the example that is cited would be unclear as a stand alone because the 'new status' is not well defined in the message and may cause confusion.
1 Reply Last reply

0